MLTX 6-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics centers on allegations that the company misrepresented the clinical efficacy of its Nanobody structure compared to traditional monoclonal antibodies, particularly in the context of the Phase 3 VELA trials [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that its product SLK shares the same molecular targets as BIMZELX, a competitor, which undermines its claimed competitive advantage [3]. - Allegations include that the company misrepresented the Nanobody's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Financial Impact - Investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and experienced significant losses are encouraged to participate in the lawsuit [4]. - Hagens Berman has a history of securing over $2.9 billion in settlements for investors in similar cases, indicating a strong potential for recovery [4][7]. Next Steps for Investors - The deadline for investors to move for appointment as lead plaintiff in the class action lawsuit is December 15, 2025 [1][5]. - Investors are urged to contact Hagens Berman for more information and to discuss their losses related to MoonLake [5][6].